Potential ferroptosis-related diagnostic and prognostic biomarkers in laryngeal cancer

Ji, Zao; Fang, Zhiyao; Dong, Xue; Wang, Jia; Wan, Xianyao; Yan, Aihui

doi:10.1007/s00405-022-07433-4

Cited by 3 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metabolic pathway analysis showed serotonergic synapse was the main different metabolic pathway, which could add new knowledge in metabolites studies ( 15 , 16 ). Together with the signaling pathway of HIF-1 and ferroptosis, serotonergic synapse-related DEGs were usually significantly enriched ( 17 ). The serotonergic synapse signal pathway was activated by the core gene protein kinase PKA and the expression of 5-HT and GABA was increased, hence insomnia symptoms were improved and anxiety was alleviated ( 18 ).…”

Section: Discussionmentioning

confidence: 99%

Plasma metabolomic signatures of breast cancer

Xu,

Zhao,

et al. 2023

Front. Med.

View full text Add to dashboard Cite

BackgroundBreast cancer is a common malignant tumor. A large number of medical evidence shows that breast cancer screening can improve the early diagnosis rate and reduce the mortality rate of breast cancer. In the present study, a wide range of targeted metabolomics profiling was conducted to investigate the plasma signatures of breast cancer.MethodsA total of 86 patients with benign breast abnormalities (L group) and 143 patients with breast cancer (E group) were recruited. We collected their plasma samples and clinical information. Metabolomic analysis, based on the coverage of a wide range of targeted metabolomics was conducted with ultraperformance liquid chromatography- triple quadrupole-linear ion trap mass spectrometer (UPLC-QTRAP-MS).ResultsWe identified 716 metabolites through widely-targeted metabolomics. Serotonergic synapse was the main different metabolic pathway. The fold change of 14 metabolites was considered significantly different (fold change <0.67 or fold change >2; p < 0.05). By combining all the 14 metabolites, we achieved differentiation of L group vs. E group (AUC = 0.792, 95%Cl: 0.662–0.809).ConclusionThis study provided new insights into plasma biomarkers for differential diagnosis of benign abnormalities and breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma metabolomic signatures of breast cancer

Xu,

Zhao,

et al. 2023

Front. Med.

View full text Add to dashboard Cite

show abstract

“…To assess and predict the effects of drugs related to ferroptosis-targeted therapy, researchers need to identify biomarkers in different tumors, such as multiple ferroptosis-associated oncoproteins, tumor suppressors, and oncogenic signal transduction pathways [ 11 ]. For example, a TGGA analysis of laryngeal cancer revealed that CDKN2A has the highest mutation frequency among the top significant differential genes that IFNG significantly correlated with tumor stage and the degree of tumor differentiation [ 110 ]. In ovarian cancer, the expression levels of ferroptosis genes are significantly correlated with patient prognosis.…”

Section: Ferroptosis In Cancer Therapeuticsmentioning

confidence: 99%

Ferroptosis and Its Multifaceted Role in Cancer: Mechanisms and Therapeutic Approach

et al. 2022

View full text Add to dashboard Cite

Ferroptosis, a new type of non-apoptotic cell death modality, is different from other modes of cell death and has been primarily found in tumor cells. Previous studies have reported that ferroptosis can be triggered by specific modulators (e.g., drugs, nutrients, and iron chelators), leading to increased intracellular lipid reactive oxygen species (ROS) accumulation and iron overload. Recent reports have shown that ferroptosis at the cellular and organism levels can prevent an inflammatory storm and cancer development. Emerging evidence suggests potential mechanisms (e.g., system Xc-, glutathione peroxidase 4 (GPX4), lipid peroxidation, glutathione (GSH), and iron chelators) are involved in ferroptosis, which may mediate biological processes such as oxidative stress and iron overload to treat cancer. To date, there are at least three pathways that mediate ferroptosis in cancer cells: system Xc-/GSH/GPX4, FSP1/CoQ10/NAD(P)H, and ATG5/ATG7/NCOA4. Here, we summarize recent advances in the occurrence and development of ferroptosis in the context of cancer, the associations between ferroptosis and various modulators, and the potential mechanisms and therapeutic strategies targeting ferroptosis for the treatment of cancer.

show abstract